Nasdaq:US$16.47 (-0.21) | HKEX:HK$26.55 (-0.10) | AIM:£2.67 (-0.01)
上一篇文章   |   下一篇文章
公告及新聞稿, 監管通知 | 2015-10-20

Director’s Share Dealing

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has:

  • purchased jointly with his spouse 4,512 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP21.95 per Share on 19 October 2015; and
  • transferred 5,626 Shares at GBP21.65 per Share from one of his investment funds to his another investment fund (jointly held with his spouse) on 19 October 2015.

Following the above transactions, the combined holding of Mr Nash and his spouse is 36,442 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.






Telephone: ​+852 2121 8200
Christian Hogg, CEO


Panmure Gordon (UK) Limited
Telephone: ​+44 20 7886 2500
Richard Gray
Andrew Potts


Citigate Dewe Rogerson
Telephone: ​+44 20 7638 9571
Anthony Carlisle, Mobile: ​+44 7973 611 888
David Dible, Mobile: ​+44 7967 566 919


About Chi-Med

Chi-Med is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: